Abstracts tagged "systemic lupus erythematosus (SLE) and pediatric rheumatology"

Abstract Number: 783 • 2019 ACR/ARP Annual Meeting
Differences in Chromatin Architecture in Treatment Naïve Pediatric Lupus Patients
Joyce Hui-Yuen¹, Frank Jenkins ², Kaiyu Jiang ³, Susan Malkiel ², Betty Diamond ⁴ and James N. Jarvis ⁵, ¹Cohen Children's Medical Center, Northwell Health, New Hyde Park, NY, ²Feinstein Institute for Medical Research, Manhasset, ³University at Buffalo Jacobs School of Medicine, Buffalo, NY, ⁴Feinstein Institutes for Medical Research, Manhasset, ⁵University at Buffalo, Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex disease likely triggered by gene-environment interactions. We have shown that most of the SLE-associated haplotypes encompass genomic…
Abstract Number: 1726 • 2019 ACR/ARP Annual Meeting
Disease Activity and Health Care Utilization Among Young Adults with Childhood-onset Lupus Transitioning to Adult Care: Follow-Up Data from the Pediatric Lupus Outcomes Study
Sara Haro¹, Erica Lawson ² and Aimee Hersh ³, ¹University of California San Francisco, San Francisco, CA, ²University of California San Francisco Benioff Children’s Hospital, San Francisco, CA, ³University of Utah, Salt Lake City, UT
Background/Purpose: Individuals with childhood-onset systemic lupus erythematosus (cSLE) must transfer from pediatric to adult health care as they enter adulthood. Previous analyses of the Pediatric…
Abstract Number: 1727 • 2019 ACR/ARP Annual Meeting
Worsening Disease Activity and Inability to Taper Corticosteroids in an Ethnically Diverse Cohort of Pediatric-Onset Lupus Patients After Transition to Adult Care
Marla Guzman¹, B.Anne Eberhard ¹ and Joyce Hui-Yuen ¹, ¹Cohen Children's Medical Center, New Hyde Park, NY
Background/Purpose: Transition of pediatric lupus (pSLE) patients from pediatric to adult rheumatology care is historically difficult and challenging. Although our division routinely assesses for transition…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].